The coagulant factor Xa induces protease-activated receptor-1 and annexin A2-dependent airway smooth muscle cytokine production and cell proliferation

American Journal of Respiratory Cell and Molecular Biology

Volumn 54, Issue 2, 2016, Pages 200-209

  Schuliga, Michael ^a   Royce, Simon G ^b   Langenbach, Shenna ^a   Berhan, Asres ^a   Harris, Trudi ^a   Keenan, Christine R ^a   Stewart, Alastair G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Airway wall remodeling; Annexin A2 hetero tetramer; Asthma; Intergin; Thrombin

Indexed keywords

1 AMINO 3 CYCLOPROPYLAMINO 7 (4 ISOPROPYLBENZYL) 7H PYRROLO[3,2 F]QUINAZOLINE; BETA1 INTEGRIN; BLOOD CLOTTING FACTOR 10A; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN D1; FIBROBLAST GROWTH FACTOR 2; HIRUDIN; INTEGRIN; INTERLEUKIN 6; LIPOCORTIN 2; MESSENGER RNA; PHOSPHOTRANSFERASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR B; PROTEINASE ACTIVATED RECEPTOR 1; SMALL INTERFERING RNA; THROMBIN; TRANSGELIN; ANXA2 PROTEIN, HUMAN; CYTOKINE; N3-CYCLOPROPYL-7-((4-(1-METHYLETHYL)PHENYL)METHYL)-7H-PYRROLO(3, 2-F)QUINAZOLINE-1,3-DIAMINE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

AIRWAY SMOOTH MUSCLE CELL; ARTICLE; ASTHMA; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; RESPIRATORY TRACT INFLAMMATION; AIRWAY REMODELING; ANTAGONISTS AND INHIBITORS; BIOPSY; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; RESPIRATORY SYSTEM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; TIME FACTOR;

AIRWAY REMODELING; ANNEXIN A2; ANTIGENS, CD29; ASTHMA; BIOPSY; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; GENE EXPRESSION REGULATION; HUMANS; MYOCYTES, SMOOTH MUSCLE; PYRROLES; QUINAZOLINES; RECEPTOR, PAR-1; RESPIRATORY SYSTEM; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; THROMBIN; TIME FACTORS; TRANSFECTION;

EID: 84963805791     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0419OC     Document Type: Article

References (52)

1. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet LP. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012;12:204.
2. Boulet LP. Irreversible airway obstruction in asthma. Curr Allergy Asthma Rep 2009;9:168-173.
3. James AL, Wenzel S. Clinical relevance of airway remodelling in airway diseases. Eur Respir J 2007;30:134-155.
4. Tubby C, Harrison T, Todd I, Fairclough L. Immunological basis of reversible and fixed airways disease. Clin Sci (Lond) 2011;121:285-296.
5. Holgate ST, Holloway J, Wilson S, Howarth PH, Haitchi HM, Babu S, Davies DE. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006;117:496-506, quiz 507.
6. Koziol-White CJ, Panettieri RA Jr. Airway smooth muscle and immunomodulation in acute exacerbations of airway disease. Immunol Rev 2011;242:178-185.
7. Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci 2012;8:1281-1290.
8. Robinson MB, Deshpande DA, Chou J, Cui W, Smith S, Langefeld C, Hastie AT, Bleecker ER, Hawkins GA. IL6 trans-signaling increases expression of airways disease genes in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2015;309:L129-L138.
9. Lambrecht BN, Hammad H. Asthma and coagulation. N Engl J Med 2013;369:1964-1966.
10. Millien VO, Lu W, Shaw J, Yuan X, Mak G, Roberts L, Song LZ, Knight JM, Creighton CJ, Luong A, et al. Cleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4. Science 2013;341:792-796.
11. Knight DA, Lim S, Scaffidi AK, Roche N, Chung KF, Stewart GA, Thompson PJ. Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma. J Allergy Clin Immunol 2001;108:797-803.
12. Scotton CJ, Krupiczojc MA, Königshoff M, Mercer PF, Lee YC, Kaminski N, Morser J, Post JM, Maher TM, Nicholson AG, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009;119:2550-2563.
13. Ortiz-Stern A, Deng X, Smoktunowicz N, Mercer PF, Chambers RC. PAR-1-dependent and PAR-independent pro-inflammatory signaling in human lung fibroblasts exposed to thrombin. J Cell Physiol 2012;227:3575-3584.
14. Tran T, Stewart AG. Protease-activated receptor (PAR)-independent growth and pro-inflammatory actions of thrombin on human cultured airway smooth muscle. Br J Pharmacol 2003;138:865-875.
15. Bhattacharjee G, Ahamed J, Pawlinski R, Liu C, Mackman N, Ruf W, Edgington TS. Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1. Circ Res 2008;102:457-464.
16. Bolton SJ, McNulty CA, Thomas RJ, Hewitt CR, Wardlaw AJ. Expression of and functional responses to protease-activated receptors on human eosinophils. J Leukoc Biol 2003;74:60-68.
17. Stenton GR, Nohara O, Déry RE, Vliagoftis H, Gilchrist M, Johri A, Wallace JL, Hollenberg MD, Moqbel R, Befus AD. Proteinaseactivated receptor (PAR)-1 and-2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2. J Pharmacol Exp Ther 2002;302:466-474.
18. Shinagawa K, Martin JA, Ploplis VA, Castellino FJ. Coagulation factor Xa modulates airway remodeling in a murine model of asthma. Am J Respir Crit Care Med 2007;175:136-143.
19. Zhu W, Bi M, Liu Y, Wang Y, Pan F, Qiu L, Guo A, Lv H, Yao P, Zhang N, et al. Thrombin promotes airway remodeling via protease-activated receptor-1 and transforming growth factor-β1 in ovalbumin-allergic rats. Inhal Toxicol 2013;25:577-586.
20. Hedhli N, Falcone DJ, Huang B, Cesarman-Maus G, Kraemer R, Zhai H, Tsirka SE, Santambrogio L, Hajjar KA. The annexin A2/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol 2012;2012:406273.
21. Schuliga M, Langenbach S, Xia YC, Qin C, Mok JS, Harris T, Mackay GA, Medcalf RL, Stewart AG. Plasminogen-stimulated inflammatory cytokine production by airway smooth muscle cells is regulated by annexin A2. Am J Respir Cell Mol Biol 2013;49:751-758.
22. Stewart AG, Xia YC, Harris T, Royce S, Hamilton JA, Schuliga M. Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling. Br J Pharmacol 2013;170:1421-1435.
23. 1. J Biol Chem 2004;279:37528-37534.
24. MacLeod TJ, Kwon M, Filipenko NR, Waisman DM. Phospholipidassociated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem 2003;278:25577-25584.
25. 6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 2006;116:1606-1614.
26. Lin L, Wu C, Hu K. Tissue plasminogen activator activates NF-κB through a pathway involving annexin A2/CD11b and integrin-linked kinase. J Am Soc Nephrol 2012;23:1329-1338.
27. Keenan CR, Mok JS, Harris T, Xia Y, Salem S, Stewart AG. Bronchial epithelial cells are rendered insensitive to glucocorticoid transactivation by transforming growth factor-β1. Respir Res 2014;15:55.
28. Schuliga MJ, See I, Ong SC, Soon L, Camoretti-Mercado B, Harris T, Stewart AG. Fibrillar collagen clamps lung mesenchymal cells in a nonproliferative and noncontractile phenotype. Am J Respir Cell Mol Biol 2009;41:731-741.
29. Ward JE, Harris T, Bamford T, Mast A, Pain MC, Robertson C, Smallwood D, Tran T, Wilson J, Stewart AG. Proliferation is not increased in airway myofibroblasts isolated from asthmatics. Eur Respir J 2008;32:362-371.
30. Schuliga M, Ong SC, Soon L, Zal F, Harris T, Stewart AG. Airway smooth muscle remodels pericellular collagen fibrils: implications for proliferation. Am J Physiol Lung Cell Mol Physiol 2010;298:L584-L592.
31. Hassan M, Jo T, Risse PA, Tolloczko B, Lemière C, Olivenstein R, Hamid Q, Martin JG. Airway smooth muscle remodeling is a dynamic process in severe long-standing asthma. J Allergy Clin Immunol 2010;125:1037-1045.
32. Wagers SS, Norton RJ, Rinaldi LM, Bates JH, Sobel BE, Irvin CG. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest 2004;114:104-111.
33. Brims FJ, Chauhan AJ, Higgins B, Shute JK. Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids. Thorax 2009;64:1037-1043.
34. Park JA, Sharif AS, Tschumperlin DJ, Lau L, Limbrey R, Howarth P, Drazen JM. Tissue factor-bearing exosome secretion from human mechanically stimulated bronchial epithelial cells in vitro and in vivo. J Allergy Clin Immunol 2012;130:1375-1383.
35. Schuliga M, Javeed A, Harris T, Xia Y, Qin C, Wang Z, Zhang X, Lee PV, Camoretti-Mercado B, Stewart AG. Transforming growth factor-β-induced differentiation of airway smooth muscle cells is inhibited by fibroblast growth factor-2. Am J Respir Cell Mol Biol 2013;48:346-353.
36. Tran T, Fernandes DJ, Schuliga M, Harris T, Landells L, Stewart AG. Stimulus-dependent glucocorticoid-resistance of GM-CSF production in human cultured airway smooth muscle. Br J Pharmacol 2005;145:123-131.
37. Schuliga M. The inflammatory actions of coagulant and fibrinolytic proteases in disease. Mediators Inflamm 2015;2015:437695.
38. Nichols HL, Saffeddine M, Theriot BS, Hegde A, Polley D, El-Mays T, Vliagoftis H, Hollenberg MD, Wilson EH, Walker JK, et al. β-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway. Proc Natl Acad Sci USA 2012;109:16660-16665.
39. Bara I, Ozier A, Girodet PO, Carvalho G, Cattiaux J, Begueret H, Thumerel M, Ousova O, Kolbeck R, Coyle AJ, et al. Role of YKL-40 in bronchial smooth muscle remodeling in asthma. Am J Respir Crit Care Med 2012;185:715-722.
40. Trian T, Girodet PO, Ousova O, Marthan R, Tunon-de-Lara JM, Berger P. RNA interference decreases PAR-2 expression and function in human airway smooth muscle cells. Am J Respir Cell Mol Biol 2006;34:49-55.
41. Kassam G, Choi KS, Ghuman J, Kang HM, Fitzpatrick SL, Zackson T, Zackson S, Toba M, Shinomiya A, Waisman DM. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 1998;273:4790-4799.
42. Swisher JF, Burton N, Bacot SM, Vogel SN, Feldman GM. Annexin A2 tetramer activates human and murine macrophages through TLR4. Blood 2010;115:549-558.
43. He KL, Sui G, Xiong H, Broekman MJ, Huang B, Marcus AJ, Hajjar KA. Feedback regulation of endothelial cell surface plasmin generation by PKC-dependent phosphorylation of annexin A2. J Biol Chem 2011;286:15428-15439.
44. 1 in airway smooth muscle suppresses exaggerated airway narrowing. J Clin Invest 2012;122:2916-2927.
45. 2 glycoprotein I antibodies. Blood 2012;119:884-893.
46. Inokuchi J, Narula N, Yee DS, Skarecky DW, Lau A, Ornstein DK, Tyson DR. Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells. Int J Cancer 2009;124:68-74.
47. Sharma MR, Rothman V, Tuszynski GP, Sharma MC. Antibodydirected targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action. Exp Mol Pathol 2006;81:136-145.
48. Tanaka T, Akatsuka S, Ozeki M, Shirase T, Hiai H, Toyokuni S. Redox regulation of annexin 2 and its implications for oxidative stressinduced renal carcinogenesis and metastasis. Oncogene 2004;23:3980-3989.
49. Fang YT, Lin CF, Wang CY, Anderson R, Lin YS. Interferon-g stimulates p11-dependent surface expression of annexin A2 in lung epithelial cells to enhance phagocytosis. J Cell Physiol 2012;227:2775-2787.
50. He KL, Deora AB, Xiong H, Ling Q, Weksler BB, Niesvizky R, Hajjar KA. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11. J Biol Chem 2008;283:19192-19200.
51. de Boer JD, Majoor CJ, van't Veer C, Bel EH, van der Poll T. Asthma and coagulation. Blood 2012;119:3236-3244.
52. Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013;52:243-254.